Literature DB >> 12684227

Regulation of renal CYP4A expression and 20-HETE synthesis by nitric oxide in pregnant rats.

Mong-Heng Wang1, Jishi Wang, Hsin-Hsin Chang, Barbara A Zand, Miao Jiang, Alberto Nasjletti, Michal Laniado-Schwartzman.   

Abstract

20-Hydroxyeicosatetraenoic acid (20-HETE), which promotes renal vasoconstriction, is formed in the rat kidney primarily by cytochrome P-450 (CYP) 4A isoforms (4A1, 4A2, 4A3, 4A8). Nitric oxide (NO) has been shown to bind to the heme moiety of the CYP4A2 protein and to inhibit 20-HETE synthesis in renal arterioles of male rats. However, it is not known whether NO interacts with and affects the activity of CYP4A1 and CYP4A3, the major renal CYP4A isoforms in female rats. Incubation of recombinant CYP4A1 and 4A3 proteins with sodium nitroprusside (SNP) shifted the absorbance at 440 nm, indicating the formation of a ferric-nitrosyl-CYP4A complex. The absorbance for CYP4A3 was about twofold higher than that of CYP4A1. Incubation of SNP or peroxynitrite (PN; 0.01-1 mM) with CYP4A recombinant membranes caused a concentration-dependent inhibition of 20-HETE synthesis, with both chemicals having a greater inhibitory effect on CYP4A3-catalyzed activity. Moreover, incubation of CYP4A1 and 4A3 proteins with PN (1 mM) resulted in nitration of tyrosine residues in both proteins. In addition, PN and SNP inhibited 20-HETE synthesis in renal microvessels from female rats by 65 and 59%, respectively. We previously showed that microvessel CYP4A1/CYP4A3 expression and 20-HETE synthesis are decreased in late pregnancy. Therefore, we investigated whether such a decrease is dependent on NO, the synthesis of which has been shown to increase in late pregnancy. Administration of NG-nitro-l-arginine methyl ester (l-NAME) to pregnant rats for 6 days (days 15-20 of pregnancy) caused a significant increase in systolic blood pressure, which was prevented by concurrent treatment with the CYP4A inhibitor 1-aminobenzotriazole (ABT). Urinary NO2/NO3 excretion decreased by 40 and 52% in l-NAME- and l-NAME + ABT-treated groups, respectively. Interestingly, renal microvessel 20-HETE synthesis showed a marked increase following l-NAME treatment, and this increase was diminished with coadministration of ABT. These results demonstrate that NO interacts with CYP4A proteins in a distinct manner and it interferes with renal microvessel 20-HETE synthesis, which may play an important role in the regulation of blood pressure and renal function during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684227     DOI: 10.1152/ajprenal.00065.2003

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  20 in total

1.  NS-398 reverses hypotension in endotoxemic rats: contribution of eicosanoids, NO, and peroxynitrite.

Authors:  Bahar Tunctan; Ayse Nihal Sari; Meltem Kacan; Demet Unsal; C Kemal Buharalioglu; Seyhan Sahan-Firat; Belma Korkmaz; John R Falck; Kafait U Malik
Journal:  Prostaglandins Other Lipid Mediat       Date:  2012-09-05       Impact factor: 3.072

2.  20-HETE-induced mitochondrial superoxide production and inflammatory phenotype in vascular smooth muscle is prevented by glucose-6-phosphate dehydrogenase inhibition.

Authors:  Anand Lakhkar; Vidhi Dhagia; Sachindra Raj Joshi; Katherine Gotlinger; Dhara Patel; Dong Sun; Michael S Wolin; Michal L Schwartzman; Sachin A Gupte
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-02-26       Impact factor: 4.733

3.  Expression of CYP 4A ω-hydroxylase and formation of 20-hydroxyeicosatetreanoic acid (20-HETE) in cultured rat brain astrocytes.

Authors:  Debebe Gebremedhin; David X Zhang; Koryn A Carver; Nicole Rau; Kevin R Rarick; Richard J Roman; David R Harder
Journal:  Prostaglandins Other Lipid Mediat       Date:  2016-05-09       Impact factor: 3.072

4.  A synthetic analogue of 20-HETE, 5,14-HEDGE, reverses endotoxin-induced hypotension via increased 20-HETE levels associated with decreased iNOS protein expression and vasodilator prostanoid production in rats.

Authors:  Tuba Cuez; Belma Korkmaz; C Kemal Buharalioglu; Seyhan Sahan-Firat; John Falck; Kafait U Malik; Bahar Tunctan
Journal:  Basic Clin Pharmacol Toxicol       Date:  2009-12-07       Impact factor: 4.080

Review 5.  Cyclooxygenase- and cytochrome P450-derived eicosanoids in stroke.

Authors:  Hui Huang; Mohamed Al-Shabrawey; Mong-Heng Wang
Journal:  Prostaglandins Other Lipid Mediat       Date:  2015-12-30       Impact factor: 3.072

6.  Prostaglandins inhibit cytochrome P450 4A activity and contribute to endotoxin-induced hypotension in rats via nitric oxide production.

Authors:  Bahar Tunctan; Fariborz A Yaghini; Anne Estes; Kafait U Malik
Journal:  Arch Pharm Res       Date:  2008-08-14       Impact factor: 4.946

7.  Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.

Authors:  Bahar Tunctan; Belma Korkmaz; Ayse Nihal Sari; Meltem Kacan; Demet Unsal; Mehmet Sami Serin; C Kemal Buharalioglu; Seyhan Sahan-Firat; Tuba Cuez; Wolf-Hagen Schunck; Vijaya L Manthati; John R Falck; Kafait U Malik
Journal:  Nitric Oxide       Date:  2013-05-14       Impact factor: 4.427

8.  20-hydroxy-5,8,11,14-eicosatetraenoic acid mediates endothelial dysfunction via IkappaB kinase-dependent endothelial nitric-oxide synthase uncoupling.

Authors:  Jennifer Cheng; Cheng-Chia Wu; Katherine H Gotlinger; Frank Zhang; John R Falck; Dubasi Narsimhaswamy; Michal Laniado Schwartzman
Journal:  J Pharmacol Exp Ther       Date:  2009-10-19       Impact factor: 4.030

9.  20-HETE-mediated cytotoxicity and apoptosis in ischemic kidney epithelial cells.

Authors:  Vani Nilakantan; Cheryl Maenpaa; Guangfu Jia; Richard J Roman; Frank Park
Journal:  Am J Physiol Renal Physiol       Date:  2008-01-02

Review 10.  Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer.

Authors:  Amanda L Johnson; Katheryne Z Edson; Rheem A Totah; Allan E Rettie
Journal:  Adv Pharmacol       Date:  2015-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.